| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
24,353 |
21,899 |
$2.67M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
23,159 |
21,432 |
$2.33M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
8,592 |
7,323 |
$2.27M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
9,740 |
8,091 |
$1.13M |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,229 |
1,887 |
$480K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,989 |
1,653 |
$478K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,554 |
1,654 |
$358K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
4,815 |
2,848 |
$287K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,053 |
819 |
$254K |
| 59025 |
Fetal non-stress test |
1,735 |
952 |
$245K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
5,979 |
5,069 |
$192K |
| 80053 |
Comprehensive metabolic panel |
8,704 |
7,430 |
$173K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
448 |
386 |
$169K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,383 |
1,021 |
$157K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
25,997 |
21,353 |
$138K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,136 |
1,061 |
$117K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
228 |
185 |
$112K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
631 |
551 |
$95K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
665 |
528 |
$95K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
374 |
262 |
$92K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,660 |
4,251 |
$78K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
33,301 |
27,699 |
$76K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,073 |
337 |
$72K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
162 |
124 |
$71K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
330 |
161 |
$71K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
594 |
203 |
$51K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
584 |
356 |
$45K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,620 |
3,142 |
$44K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,644 |
3,421 |
$43K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
738 |
537 |
$43K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
387 |
333 |
$40K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
390 |
375 |
$38K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
597 |
457 |
$37K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
2,397 |
2,235 |
$36K |
| G0378 |
Hospital observation service, per hour |
962 |
535 |
$36K |
| 80061 |
Lipid panel |
2,862 |
2,627 |
$34K |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
216 |
190 |
$31K |
| 80076 |
|
11,522 |
9,915 |
$30K |
| 84484 |
|
8,389 |
6,301 |
$29K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,103 |
1,010 |
$28K |
| 86592 |
|
987 |
913 |
$27K |
| 86900 |
|
1,141 |
959 |
$26K |
| 80069 |
|
1,644 |
1,465 |
$26K |
| 83970 |
|
1,264 |
1,168 |
$25K |
| 71046 |
Radiologic examination, chest; 2 views |
2,150 |
2,001 |
$24K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,107 |
1,015 |
$24K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,857 |
3,180 |
$23K |
| 36415 |
Collection of venous blood by venipuncture |
14,587 |
12,022 |
$23K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,185 |
1,513 |
$22K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
71 |
51 |
$22K |
| 87806 |
|
461 |
414 |
$20K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
521 |
475 |
$18K |
| 82607 |
|
1,102 |
1,032 |
$16K |
| 86850 |
|
1,000 |
856 |
$12K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
112 |
87 |
$12K |
| 71045 |
Radiologic examination, chest; single view |
9,829 |
8,475 |
$12K |
| 72110 |
|
280 |
238 |
$12K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
181 |
130 |
$11K |
| 82728 |
|
740 |
674 |
$11K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,297 |
1,067 |
$11K |
| 74018 |
|
451 |
347 |
$11K |
| 71250 |
|
132 |
106 |
$11K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
519 |
475 |
$11K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
12,103 |
10,200 |
$10K |
| 86803 |
|
516 |
457 |
$10K |
| J3490 |
Unclassified drugs |
840 |
625 |
$10K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
576 |
544 |
$9K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
249 |
235 |
$9K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
76 |
74 |
$9K |
| 84439 |
|
748 |
627 |
$9K |
| 93017 |
|
119 |
92 |
$8K |
| 86901 |
|
1,141 |
959 |
$8K |
| 76775 |
|
74 |
61 |
$8K |
| 87340 |
|
519 |
448 |
$8K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
415 |
329 |
$8K |
| 82746 |
|
827 |
774 |
$7K |
| 83550 |
|
770 |
708 |
$7K |
| 72131 |
|
122 |
87 |
$7K |
| 84702 |
|
740 |
575 |
$7K |
| 84550 |
|
1,476 |
1,255 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
6,118 |
5,160 |
$6K |
| 83540 |
|
787 |
719 |
$6K |
| 93976 |
|
83 |
68 |
$6K |
| 97161 |
|
161 |
125 |
$6K |
| 87081 |
|
947 |
849 |
$6K |
| 73030 |
|
303 |
237 |
$6K |
| 73630 |
|
607 |
492 |
$6K |
| 85027 |
|
1,432 |
979 |
$5K |
| 81001 |
|
11,276 |
9,844 |
$5K |
| 85014 |
|
917 |
835 |
$5K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
25 |
25 |
$5K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
28 |
25 |
$5K |
| 93971 |
|
46 |
37 |
$5K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
9,781 |
6,082 |
$5K |
| 86762 |
|
298 |
274 |
$4K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
13,573 |
11,388 |
$4K |
| 82950 |
|
332 |
311 |
$4K |
| 76642 |
|
36 |
25 |
$4K |
| 96367 |
|
38 |
24 |
$4K |
| 73610 |
|
337 |
277 |
$4K |
| 90715 |
|
250 |
205 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
7,854 |
6,800 |
$4K |
| 85018 |
|
1,491 |
1,180 |
$3K |
| 83735 |
|
1,069 |
731 |
$3K |
| 85610 |
|
2,894 |
2,205 |
$3K |
| 73130 |
|
319 |
264 |
$3K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
14 |
14 |
$3K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
18 |
12 |
$3K |
| 84153 |
|
183 |
163 |
$3K |
| 76536 |
|
28 |
26 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
16 |
12 |
$3K |
| 93356 |
|
12 |
12 |
$3K |
| 73502 |
|
120 |
85 |
$3K |
| 71271 |
|
14 |
13 |
$3K |
| 12001 |
|
20 |
15 |
$2K |
| 82962 |
|
2,131 |
1,172 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,124 |
3,728 |
$2K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
13 |
12 |
$2K |
| 83690 |
|
7,948 |
6,747 |
$2K |
| 81003 |
|
4,976 |
4,362 |
$2K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
12 |
12 |
$2K |
| 82565 |
|
309 |
245 |
$2K |
| 86880 |
|
149 |
129 |
$2K |
| 83605 |
|
1,538 |
1,122 |
$2K |
| 83880 |
|
1,010 |
759 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
9,850 |
7,973 |
$2K |
| 88142 |
|
78 |
78 |
$1K |
| 70486 |
|
15 |
13 |
$1K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
1,854 |
916 |
$1K |
| 83525 |
|
55 |
52 |
$1K |
| 96376 |
|
889 |
508 |
$1K |
| 85379 |
|
1,571 |
1,280 |
$1K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
6,632 |
4,740 |
$1K |
| 85730 |
|
2,264 |
1,794 |
$1K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
965 |
639 |
$1K |
| 94664 |
|
218 |
111 |
$1K |
| 82043 |
|
159 |
146 |
$1K |
| 86140 |
|
88 |
74 |
$1K |
| 81025 |
|
5,417 |
4,705 |
$1K |
| 87040 |
|
737 |
475 |
$1K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
58 |
30 |
$1K |
| 73110 |
|
58 |
54 |
$1K |
| 82570 |
|
327 |
221 |
$994.98 |
| 87186 |
|
941 |
776 |
$986.21 |
| 82784 |
|
59 |
58 |
$982.14 |
| 74420 |
|
15 |
13 |
$963.32 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,725 |
1,083 |
$897.09 |
| 83615 |
|
339 |
226 |
$884.11 |
| 87070 |
|
1,241 |
999 |
$757.43 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
32 |
29 |
$755.61 |
| 76801 |
|
13 |
13 |
$738.33 |
| 82150 |
|
1,175 |
997 |
$730.26 |
| 84156 |
|
335 |
225 |
$729.62 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
13 |
13 |
$676.68 |
| 84100 |
|
183 |
108 |
$637.12 |
| 82803 |
|
404 |
257 |
$598.05 |
| 84403 |
|
18 |
12 |
$578.17 |
| 82105 |
|
19 |
16 |
$466.40 |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
38 |
34 |
$463.57 |
| J7050 |
Infusion, normal saline solution, 250 cc |
3,053 |
1,601 |
$438.17 |
| 36591 |
|
463 |
276 |
$421.13 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
17 |
15 |
$418.97 |
| 87280 |
|
588 |
520 |
$399.63 |
| 86706 |
|
28 |
28 |
$394.51 |
| 85651 |
|
71 |
60 |
$383.60 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,798 |
2,106 |
$379.39 |
| 73560 |
|
193 |
139 |
$361.28 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
16 |
12 |
$350.68 |
| 00731 |
|
51 |
44 |
$328.72 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
944 |
634 |
$322.14 |
| 83516 |
|
14 |
12 |
$322.10 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
8,879 |
7,047 |
$313.74 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
6,228 |
5,360 |
$306.50 |
| 73590 |
|
34 |
24 |
$302.02 |
| 97597 |
|
36 |
26 |
$292.52 |
| 87077 |
|
726 |
606 |
$281.83 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
735 |
461 |
$233.60 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
930 |
652 |
$206.87 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,131 |
710 |
$175.61 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,338 |
3,633 |
$167.72 |
| 85007 |
|
144 |
98 |
$162.09 |
| 87088 |
|
35 |
33 |
$148.28 |
| 86704 |
|
12 |
12 |
$134.44 |
| 82947 |
|
14 |
13 |
$129.13 |
| J1644 |
Injection, heparin sodium, per 1000 units |
523 |
196 |
$124.12 |
| 94762 |
|
879 |
812 |
$121.55 |
| 87205 |
|
1,019 |
787 |
$106.75 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,727 |
2,189 |
$76.65 |
| 88304 |
|
64 |
44 |
$74.71 |
| C9113 |
Injection, pantoprazole sodium, per vial |
50 |
30 |
$67.59 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
140 |
98 |
$66.00 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
50 |
26 |
$61.75 |
| 84145 |
|
115 |
71 |
$58.73 |
| 85652 |
|
12 |
12 |
$54.31 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
137 |
110 |
$52.11 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
905 |
677 |
$46.40 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
281 |
230 |
$40.01 |
| 0012A |
|
25 |
24 |
$37.98 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
854 |
586 |
$35.04 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
375 |
272 |
$33.42 |
| J2060 |
Injection, lorazepam, 2 mg |
394 |
278 |
$31.79 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
19 |
13 |
$29.34 |
| 82010 |
|
101 |
68 |
$29.26 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
329 |
246 |
$22.74 |
| 80329 |
|
13 |
12 |
$22.48 |
| 80348 |
|
158 |
124 |
$17.13 |
| 82247 |
|
23 |
13 |
$16.63 |
| 84703 |
|
13 |
12 |
$14.88 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,141 |
832 |
$11.72 |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
184 |
176 |
$10.61 |
| J2704 |
Injection, propofol, 10 mg |
329 |
313 |
$9.36 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
45 |
42 |
$7.15 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
20 |
13 |
$6.30 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
252 |
207 |
$3.95 |
| C1769 |
Guide wire |
278 |
177 |
$0.00 |
| 94760 |
|
4,339 |
3,440 |
$0.00 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
80 |
70 |
$0.00 |
| 91301 |
|
54 |
48 |
$0.00 |
| J2785 |
Injection, regadenoson, 0.1 mg |
18 |
12 |
$0.00 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
75 |
53 |
$0.00 |
| 88342 |
|
19 |
15 |
$0.00 |
| 0011A |
|
32 |
31 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
32 |
19 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
390 |
311 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
51 |
35 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
21 |
14 |
$0.00 |
| 84450 |
|
22 |
12 |
$0.00 |
| 00812 |
|
13 |
13 |
$0.00 |
| 84460 |
|
22 |
12 |
$0.00 |
| 80305 |
|
27 |
25 |
$0.00 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
14 |
13 |
$0.00 |